Sylwia also demonstrated that an optimized targeted B7-H3 immunotherapy drug was effective in treating 68 AML patient samples, with flow cytometry analysis showing that the optimized anti-B7-H3 drug induces NK cell activation and AML cell death by inhibiting B7-H3 expression on AML cells (140). Here, CD276 is linked to acute myeloid leukemia.